(1.23%) 5 110.50 points
(0.53%) 38 287 points
(2.23%) 15 959 points
(0.18%) $83.72
(-1.16%) $1.619
(0.34%) $2 350.50
(-0.46%) $27.23
(0.10%) $921.45
(0.31%) $0.935
(0.65%) $11.02
(0.15%) $0.800
(-0.31%) $91.88
Live Chart Being Loaded With Signals
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis...
Stats | |
---|---|
Today's Volume | 1 337.00 |
Average Volume | 6 127.00 |
Market Cap | 173.41M |
EPS | $0 ( 2024-04-11 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.72 |
ATR14 | $0 (0.00%) |
Genfit SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Genfit SA Financials
Annual | 2023 |
Revenue: | $28.57M |
Gross Profit: | $28.22M (98.81 %) |
EPS: | $-0.580 |
FY | 2023 |
Revenue: | $28.57M |
Gross Profit: | $28.22M (98.81 %) |
EPS: | $-0.580 |
FY | 2022 |
Revenue: | $20.20M |
Gross Profit: | $19.95M (98.77 %) |
EPS: | $-0.480 |
FY | 2021 |
Revenue: | $80.07M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $1.510 |
Financial Reports:
No articles found.
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators